Revvity Signals described how AI is being used to manage the growing review burden in late-stage clinical development, arguing that automation is becoming necessary as Phase III trials generate millions of data points. The company highlighted AI-enabled listing generation, signal detection, and documented review workflows while emphasizing governance and traceability requirements for regulatory acceptance.